Xinan Qiao

c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia

J. Taub, Hai Lin, H. Edwards, 2022, Apoptosis.

Inhibition of Mcl-1 Synergistically Enhances the Antileukemic Activity of Gilteritinib and MRX-2843 in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

J. Taub, H. Edwards, Guan Wang, 2022, Cells.

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML

Jing Li, J. Taub, Tristan E. Knight, 2021, Blood Cancer Journal.

Calf Spleen Extractive Injection protects mice against cyclophosphamide-induced hematopoietic injury through G-CSF-mediated JAK2/STAT3 signaling

Yan Liu, Wenqian Lu, D. Jia, 2017, Scientific Reports.

Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia

J. Taub, Tristan E. Knight, L. Polin, 2019, Clinical Cancer Research.

Co-targeting of HDAC, PI3K, and Bcl-2 Results in Metabolic and Transcriptional Reprogramming and Decreased Mitochondrial Function in Acute Myeloid Leukemia.

A. Dombkowski, X. Bao, J. Taub, 2022, Biochemical pharmacology.

Acquired Resistance to Venetoclax plus Azacitidine in Acute Myeloid Leukemia: in vitro Models and Mechanisms.

X. Bao, J. Taub, M. Hüttemann, 2023, Biochemical pharmacology.